The substance has been shown to be effective in reducing the viral load within eight days of a single dose, as well as limiting the risk of hospitalization or death.
Novartis and Molecular Partners laboratories claim Monday the success of their interim clinical study “Empathy” on intravenous ensovibep once morest Covid-19. The substance has been shown to be effective in reducing viral load within eight days of a single dose, as well as limiting the risk of hospitalization or death, the partners say in separate releases.
The multinational pharmaceutical company confirms in the wake of its intention to acquire the rights to the experimental antiviral. Its modest counterpart from Zurich recalls that the operation will allow it to receive a milestone payment of 150 million francs, in addition to 22% commissions on sales in the event of approval.
Ensovibep was discovered by Molecular Partners and since October 2020 has been the subject of a collaboration with Novartis. The latter took over the clinical studies last spring, during the transition to phase II.
